# US 4,396,605 A · Bis-thymosine .alpha.-1 compounds > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 4,396,605 A - Document ID: US4396605A - Status: Granted - Kind: A - Application number: 06/367,817 - Filed: 1982-04-12 - Granted: 1983-08-02 - Earliest claimed: 1981-09-18 - Assignees: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V. - Inventors: Christian Birr - Web page: https://patentgrep.com/patent/US4396605A ## CPC - C07K 14/57581: {Thymosin; Related peptides} - A61P 37/04: Immunostimulants - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups - Y10S 530/837: Lymph; lymph-glands; thymus - Y10S 930/18: Thymus derived hormone or factor; related peptides - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS - Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS ## Abstract Bis-thymosine .alpha.-1 consisting of two desacetylthymosine .alpha.-1 un N-terminally linked by a bridge bond of 1 to 10 carbon atoms, especially an .alpha.,.omega.-diacyl residue with 2 to 10 carbon atoms. This new compound is made by converting a synthetic desacetylthymosine .alpha.-1 in which all functional groups of amino acids 1 through 28, except the N-terminal group, are blocked by protective groups conventional in peptide synthesis with a coupling compound of 1 to 10 carbon atoms and that reacts with NH.sub.2 groups, in a polar solvent, and then removing the protective groups. ## Claims ### Claim 1 Bis-thymosine.alpha.-1 compound of the formula T.sub.2 R in which T is a desacetylthymosine.alpha.-1 residue, R is a .alpha.,.omega.-diacyl residue of 2 to 10 carbon atoms, optionally containing at least one of an aromatic nucleus, OH-groups, NH.sub.2 -groups, halogen atoms, and olefinic double bonds, or where R is a CO-group. ### Claim 2 (depends on 1) Bis-thymosine.alpha.-1 compound as claimed in claim 1, wherein R is a .alpha.,.omega.-diacyl residue of 2 to 10 carbon atoms. ### Claim 3 (depends on 1) Bis-thymosine.alpha.-1 compound as claimed in claim 1, wherein R is a CO-group. ### Claim 4 (depends on 1) Bis-thymosine.alpha.-1 compound as claimed in claim 1, wherein R is a .alpha.,.omega.-diacyl residue containing an aromatic nucleus. ### Claim 5 (depends on 1) Bis-thymosine.alpha.-1 compound as claimed in claim 1, wherein R is a .alpha.,.omega.-diacyl residue containing at least one olefinic double bond. ### Claim 6 (depends on 1) Bis-thymosine.alpha.-1 compound as claimed in claim 1, wherein R is a .alpha.,.omega.-diacyl residue containing at least one of OH, NH.sub.2 and halogen. ### Claim 7 (depends on 1) Bis-thymosine.alpha.-1 compound as claimed in claim 1, wherein R is derived from phosgene. ### Claim 8 (depends on 1) Bis-thymosine.alpha.-1 compound as claimed in claim 1, wherein R is derived from oxalic acid. ### Claim 9 (depends on 1) Bis-thymosine.alpha.-1 compound as claimed in claim 1, wherein R is derived from succinic acid. ### Claim 10 (depends on 1) Bis-thymosine.alpha.-1 compound as claimed in claim 1, wherein R is derived from aspartic acid. ### Claim 11 (depends on 1) Bis-thymosine.alpha.-1 compound as claimed in claim 1, wherein R is derived from glutamic acid. ### Claim 12 (depends on 1) Bis-thymosine.alpha.-1 compound as claimed in claim 1, wherein R is derived from maleic acid. ### Claim 13 (depends on 1) Bis-thymosine.alpha.-1 compound as claimed in claim 1, wherein R is derived from phenylenediacetic acid. ### Claim 14 Succinyl-bis-desacetylthymosine.alpha.-1. ### Claim 15 (depends on 1) Pharmaceutical composition for stimulating immuno-defense cells which composition contains a pharmaceutically acceptable carrier and, in effective amount, a bis-thymosine.alpha.-1 compound as claimed in claim 1. ### Claim 16 (depends on 1) Method of stimulating immuno-defense cells which method comprises administering thereto a pharmaceutically effective amount of a bis-thymosine.alpha.-1 compound as claimed in claim 1.